

WHO Guidelines on the prevention of surgical site infections

Professor Benedetta Allegranzi Infection Prevention & Control Global Unit, WHO HQ



WHO core components for effective IPC programmes

8 Core components

- 8 Facility level
- 6 National level
- 11 evidence*-based recommendations
- 3 good practice statements
 - * Evidence from LMICs:
 - 7 high-quality studies
 - 22 lower quality



IPC PROGRAMMES and all relevant programme linkages

EDUCATION

GUIDELINES

ONITORING


AUDIT AND




R= recommendation; GPS: good practice statement









SSI epidemiology and burden




- Second and third most frequent type of HAI in Europe and the USA
- Most frequent type of HAI on admission (67% in the USA, 33% in Europe)
 - **SSI incidence** (per 100 procedures)
 - USA 2014: 1.9%
 - **Europe** 2013–14: 0.6–9.5%
 - > 800 000 SSIs leading to over 16 000 deaths, annually
 - EUR 1.5 billion-19 billion: total annual extra cost to health systems
 - AMR: 39–51% of SSI pathogens are resistant to standard prophylactic antibiotics in the USA

Sources:

- National and state healthcare-associated infections progress report. Atlanta (GA): National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention; 2016 (<u>http://www.cdc.gov/HAI/pdfs/progressreport/</u>hai-progress-report.pdf, accessed 10 August 2016).
- ECDC. Annual epidemiological report 2016 surgical site infections. Stockholm: European Centre for Disease Prevention and Control; 2016 <a href="https://ecdc.europa.eu/en/publications-data/surgical-site-infectionsannual-site-infections-data/surgical-site-infections-data/surgical-site-infections-data/surgical-site-infections-data/surgical-site-infections-data/surgical-site-infecting-site-infecting-surgical-site-infections-data/surgical-site-infe
- Cassini A. et al. "Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study", PLoS Med, Vol. 13, pp. 1-16, http://dx.doi.org/10.1371/journal.pmed.1002150
- Badia, J. et al. (2017), "Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries", J Hosp Infect 2017; 96: 1-15, http://dx.doi.org/10.1016/j.jhin.2017.03.004
- Suetens C et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys 2016 to 2017. Euro Surveill. 2018;23(46):pii=1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516

SSI incidence in LMICs (1995–2015, 107 studies)






Pooled cumulative incidence:

11.2% per 100 surgical patients (95% CI: 9.7–12.8)
5.9 per 100 surgical procedures (95% CI: 4.8–7.1) *I*² = 99.8%

Impact of increasing AMR on SSI





- Scenarios of 10% and 100% reduction in the effectiveness of surgical antibiotic prophylaxis:
 - From 44 000 to 439 000 additional
 postoperative infections would occur
 each year in the EU (increases of
 5% and 50% relative to current
 estimates, respectively)
- 307 000 post-intervention deaths would occur each year if no effective antimicrobial treatment was available

- Badia, J. et al. (2017), "Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries", J Hosp Infect 2017; 96: 1-15, http://dx.doi.org/10.1016/j.jhin.2017.03.004
- Surveillance of surgical site infections and prevention indicators in European hospitals HAI-Net SSI protocol, version 2.2 Surveillance of surgical site infections and prevention indicators in European hospitals, ECDC, http://dx.doi.org/10.2900/260119

OECD (2018), Stemming the Superbug Tide: Just A Few Dollars More, OECD Publishing, Paris. https://doi.org/10.1787/9789264307599-en







WHO Guidelines, updated 2018





- 28 systematic reviews & meta-analyses
- **29** recommendations

World Health Organization

30 core chapters

http://apps.who.int/iris/bitstream/10665/250680/1/9789241549882-eng.pdf?ua=1 http://www.who.int/infection-prevention/publications/ssi-web-appendices/en/

Methods for recommendation development (1)



Development of recommendations

- Recommendations were based on systematic reviews and using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, based on scientific evidence and expert consensus/country experience.
- The decision-making process involved expert discussion about the evidence of effectiveness of the preventive measure, any harms it may cause, resource implications of implementation and views of patients and professionals.

Source: Global guidelines for the prevention of surgical site infection. Geneva: World Health Organization; 2016 (http://www.who.int/infection-prevention/publications/ssi-prevention-guidelines/en/).

Methods for recommendation development (2)




Strength of recommendations – two types

- "Strong" the expert panel was confident that benefits outweighed risks, that the measure was considered to be adaptable for implementation in most (if not all) situations and that patients should receive the intervention as standard.
- "Conditional" the expert panel considered that the benefits of intervention probably outweighed the risks or that a more structured decision-making process should be undertaken, based on stakeholder consultation and involvement of patients and health care professionals.

SSI prevention throughout the surgical patient journey







http://www.who.int/infection-prevention/tools/surgical/reminders-advocacy/en/

WHO recommendations for SSI prevention (1)









WHO recommendations for SSI prevention (2)






WHO recommendations for SSI prevention (3)






WHO Recommendations for SSI Prevention for the <u>Preoperative Period</u>



http://who.int/infection-prevention/publications/ssi-guidelines/en




WHO Recommendations for SSI Prevention for the Pre- and/or Intraoperative Period



http://who.int/infection-prevention/publications/ssi-guidelines/en




WHO Recommendations for SSI Prevention for the <u>Postoperative Period</u>



http://who.int/infection-prevention/publications/ssi-guidelines/en







Operational manual for the WHO SSI prevention recommendations.

This implementation manual is designed to be used by all persons concerned by the prevention of SSI in all health care settings, irrespective of the country.

Launched in December 2018

http://www.who.int/infection-prevention/tools/surgical/en/

Strong recommendation – preoperative measures: treatment of *S. aureus* **nasal carriers (1)**



Patients undergoing cardiothoracic and orthopaedic surgery with known nasal carriage of *S. aureus* should receive perioperative intranasal applications of mupirocin 2% ointment with or without a combination of chlorhexidine gluconate (CHG) body wash.

Consider treating patients with known nasal carriage of *S. aureus* undergoing other types of surgery with perioperative intranasal applications of mupirocin 2% ointment with or without a combination of CHG body wash (associated conditional recommendation).

Strong recommendation – preoperative measures: treatment of *S. aureus* **nasal carriers (2)**



Why

- *S. aureus* is a leading HAI pathogen worldwide.
- *S. aureus* infections impose a high burden on the patient and the health system and are a known cause of postoperative wound infections.
- Nasal carriage of S. aureus is a risk factor for subsequent infection in a patient. It has been shown repeatedly that a large proportion of HAIs due to S. aureus originate from patients' own flora.

Strong recommendation – preoperative measures: treatment of *S. aureus* **nasal carriers (3)**



Notes

- Screening of patients for *S. aureus* varies between and within countries and is dependent on several factors including cost–effectiveness and local epidemiology.
- This recommendation only applies to facilities where screening (nasal swabs sent to a laboratory) for *S. aureus* is feasible, and may not apply to settings with high prevalence of mupirocin resistance.

Practical points

- This recommendation can be applicable to pre- and perioperative periods (depending on local conditions for treatment).
- The application of mupirocin is usually twice a day for 5–7 days before surgery or from the day of hospital admission to the day of surgery.
- Ensure that potential allergic reactions to mupirocin are investigated and recorded and patient communications and record keeping regarding this treatment occur.



SURGICA Key fac carrie	L SITE INFE(ts on decolo rs of <i>Staphy</i> ow	onization dococcus	of nasal <i>aureus</i>
The 2016 WHO Elobal guidelines for the prevent Staphylococcus aurous undergoing: cardiothoracic and orthopaedic surger decidanzary using intransal applications or obstream, with ar without a combination of pluconate ((Fe)) body wath Strong recomm	tion of surgical site infection y should be of mupirocin 2% chlorhexidine	s recommend that pati other types of surge of mupiracin 2% cintr	
This recommendation applies to facilities where mpirocin resistance. Based on the lack of evidence, this recommend	-		xly to settings with a high prevalence of
WHAT should be done? WHAT should be done? Involve patients and ask for their collabore instructions. Outpatients: provide clear instructions on locally to perform a Child body wash before upplies??! Wead, Child 2-48 seap body we - Inpatients: the same instructions for patients.	how to correctly administer i the operation (for more detail sh should be applied in comi	ntranasal applications led information, see bel bination with clean, rur	of mupirocin 2% cintment and, if advised low "When should the recommendation be wing water.
Support access to necessary products provision to patients may be required or desirable in some countries: nasal mupicical 7% ointment CHG 2-4% scap body wish. Monitor mupirocin resistance, if mupirocin is used. Decolonization with mupirocin is used. Decolonization with mupirocin auroscation with be performed on knows. Surves carries only in order to avoid unnecessary treatment and the spread of resistance.	For other types of s careful local evalua and how to apply this particular, regarding f identification in a bro- population, priority of over other preventive considered, as well as	rtion about whether recommendation. In easibility of carrier ader surgical patient this intervention measures should be	Support the local screening policy of patients to detect 3 avevas carriaga- consider the local rates of 3 avevas and methrillin-resistant 3 avevas (MRSA) and patient-related factors. Specifically lock for previous 3 avevas infections, known carrier status of community-acquired MRSA, and collarization body sites
	 Ensure that potential to mupirocin and CHG and recorded. 		other than the nose.

Source: http://www.who.int/infectionprevention/tools/surgical/training_education/tools/surgical/tool

Strong recommendation – preoperative measures: mechanical bowel preparation (MBP) and preoperative oral antibiotics

World Healt

1.MBP alone (*without* administration of oral antibiotics) should *not* be used in adult patients undergoing elective **colorectal surgery** (strong recommendation).

2. Preoperative oral antibiotics combined with MBP should be used to reduce the risk of SSI in adult patients undergoing elective colorectal surgery (conditional recommendation).

Why?

- Evidence (moderate quality) showed that preoperative MBP alone has neither • benefit nor harm in reducing SSI rate when compared to performing no MBP.
- Further evidence (moderate quality) showed that **preoperative MBP combined** ٠ with oral antibiotics reduced SSI when compared to MBP alone.

Practical points



- This recommendation applies only to the preoperative period and should not be referred to as "selective digestive decontamination".
- Local considerations may determine variations in decisions about the type of MBP regimen and oral antibiotics, and the drug of choice for intravenous antibiotic prophylaxis (availability, resistance data and volume of surgical activity).
- The combination of drugs used should guarantee activity against both facultative gram-negative and anaerobic bacteria. In most studies, oral aminoglycosides were combined with metronidazole or erythromycin.

Strong recommendations – preoperative measures: hair removal



In patients undergoing any surgical procedure, hair should either *not* be removed or, if absolutely necessary, should only be removed with clippers. Shaving is strongly discouraged at all times, whether preoperatively or in the operating room.

Why?

- Removal of hair by any method has no benefit on the incidence of postoperative infection compared to no hair removal.
- The incidence of SSI is higher when hair removal is performed by razor than by clippers because shaving causes small abrasions to the skin.
- Most studies support that hair removal, if any, should be done immediately before operation.
- Note: the evidence showed that use of depilatory creams has no benefit (no lower SSI risk) compared with shaving; in addition, these sometimes produce hypersensitivity reactions. WHO does not recommend their use.

Practical points

- It has been noted that, when hair absolutely must be removed (when presence of hair will interfere with the operation), a single-use head should be used for electric clippers.
- Women may prefer shaving the genital area before surgery and may even come to the hospital already shaved because of cultural norms – this is something that should be avoided and should be addressed in training and education targeted at patients.







Source: <u>http://www.who.int/infection-</u> prevention/tools/surgical/training_education/ n/en/

Strong recommendations – preoperative measures: Surgical antibiotic prophylaxis (SAP) timing (1)



SAP should be administered before the surgical incision, when indicated.

SAP should be administered within 120 minutes before incision, while considering the half-life of the antibiotic.

Why?

- Correct preoperative administration timing to achieve adequate concentration of drug at the site of incision at the beginning of the operation (highest risk of surgical site contamination) is critical. Incorrect (before 120 minutes or after incision) timing can lead to an increased risk of SSI.
- Correct antibiotic type according to the procedure and patient history aims to destroy the bacteria most frequently found at the operation site and to be safe for the patient.

Strong recommendations – preoperative measures: SAP timing (2)



Notes

- Correct dosage is important to have the right antibiotic concentration at the operation site throughout the entire operation.
- Correct use of SAP is important not only to prevent SSI but also to avoid emergence of antimicrobial-resistant pathogens that can cause more serious disease to the patient.

Practical points

 Half-life of antibiotics may affect serum and tissue concentrations – half-life of



administered antibiotics should be taken into account in order to establish the exact time of administration within the 120-minute recommendation.

- Antibiotics with a <u>short half-life</u> (e.g. cefazolin, cefoxitin and penicillins in general) should be administered <u>closer to the incision time</u> (<60 minutes).
- Underlying factors in patients may also affect drug disposition (e.g. malnourishment, obesity, cachexia or renal disease with protein loss may result in <u>suboptimal antibiotic exposure</u> through <u>increased antibiotic clearance</u> in the presence of normal or augmented renal function).
- An example of surgery not requiring SAP is clean orthopaedic surgery not involving implantation of foreign materials.
- There are recommendations about redosing if a procedure exceeds two half-lives of the drug or if there is excessive blood loss, but not enough evidence is available to make this confirmed protocols.

Strong recommendations – preoperative measures: surgical hand preparation



Surgical hand preparation should be performed by either scrubbing with a suitable antimicrobial soap and water or using a suitable alcohol-based handrub (ABHR) before donning sterile gloves.

Why?

- It is vitally important to maintain the lowest possible contamination of the surgical field (even when sterile gloves are worn – glove punctures can occur). Hand preparation should reduce the release of skin bacteria from the hands to the open wound.
- Surgical hand preparation should eliminate transient flora and reduce resident flora.
- Moderate-quality evidence shows the equivalence of ABHR and use of antimicrobial soap and water.
- Note: the hands of the surgical team should be clean upon entering the operating room.

Practical points



- Once in the operating area, repeating handrubbing or scrubbing without an additional prior handwash is recommended before switching to the next procedure.
- Surgical handscrub and surgical handrub with an alcohol-based product should not be combined sequentially.
- Alcohol-based handrubs can be produced locally (more on this later).
- The use of alcohol on patients or health workers who for religious reasons may object has been addressed in the WHO guidelines on hand hygiene in health care, with cultural and religious leaders providing supporting statements to overcome barriers.
- Skin irritation can happen and health facilities should be alert to deal with such situations.

Source: WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009 (http://www.who.int/infection-prevention/tools/core-components/en/).

Strong recommendations – preoperative measures: surgical site skin preparation



Alcohol-based antiseptic solutions based on CHG for surgical site skin preparation should be used in patients undergoing surgical procedures.

Why?

- This measure reduces the microbial load on the patient's skin as much as possible before incision.
- Alcohol-based CHG is more effective in reducing SSI rates compared to alcohol-based povidone-iodine.
- **Notes:** intact skin prep should be done prior to incision in the operating room. This recommendation is not proven for paediatric patients.

Practical points

- Alcohol-based solutions should **not** be in contact with mucosa or eyes and should not be used on newborns.
- Ensure operating and ward staff are aware that CHG can cause skin irritation.
- The use of alcohol on patients or health workers who for religious reasons may object has been addressed in the WHO guidelines on hand hygiene in health care, with cultural and religious leaders providing supporting statements to overcome barriers.
- Alcohol/CHG-based skin preparation solutions can be produced locally if needed (more on this later).



- ensure correct placement of
 patient (to avoid movement after
 skin prep but considering areas
 of skin that might be prone to
 breaking down due to the
 pressure of being in one position
 for too long) and skin examine;
- protect health workers against splashing – gloves should be worn but changed once the skin prep is complete;
- ensure skin preparation is not removed/washed off before draping.

Surgical skin preparation in practice: key resources

How to perform

PREOPERATIVE SURGICAL SITE

SKIN PREPARATION

An educational video produced by the


World Health Organization



World He Organizat SURGICAL SITE INFECTION PREVENTION Key facts on surgical site skin preparation THINGS YOU SHOULD KNOW What does the World Health Organization (WHO) recommend? The 2016 WHO Global guidelines for the prevention of surgical site infections (SSIs) recommend that alcohol-based antiseptic solutions containing chlorhexidine gluconate (CHG) should be used for surgical site skin preparation in patients undergoing surgical procedures. Surgical site skin preparation is the preoperative treatment (cleaning and disinfection) of the patient's intact skin done prior to surgery within the operating room (OR). T WHAT should be done? Carefully wash and clean the skin Use an alcohol-based CHG solution Apply the solution using sterile around the incision site. Full-body (usually, a 2% chlorhexidine isopropanol gauze and instruments with washing with detergents or antiseptics solution) for surgical site skin movements from clean to dirty areas should be performed before the preparation. starting from the centre of the incision operation and outside of the OR (see site and moving outwards, maintaining "Key facts on patient bathing and hair an aseptic technique. Then, allow to remmal"] dry fully before incision. Ensure that the drapes are not > Ensure that any adverse events Record known information on surgical saturated with alcohol or that the associated with the solutions used are site skin preparation on surveillance alcohol-based solution has not formed a investigated and recorded. forms and in patient records (for pool underneath the patient before example, that it has been performed operating. according to standard procedures and no adverse event occurred, time, and product used) Support colleagues to adhere to this recommendation and be an advocate for it Local production > If the commercial availability of CHG in an >> Alcohol-based solutions should not be > A video on the appropriate procedure alcohol-based solution is limited or too used on neonates or be in contact with to be used for surgical site skin expensive, the use of a 2% chlorhexidine preparation is available from WHO at mucosa or eyes. CHG solutions must not isopropanol solution for skin disinfection http://www.who.int/infection-prev be allowed to come into contact with the

brain, meninges, eye or middle ear.

ention/tools/surgical/training_ed



0:02 / 5:03

Source: http://www.who.int/infection-prevention/tools/surgical/training_education/en/

produced locally according to the

E 🦛 🕂

Strong recommendations – intra- and postoperative measures: SAP prolongation



SAP administration should *not* be prolonged after completion of the operation.


Why?

- Moderate-quality evidence shows that prolonged SAP postoperatively has no benefit in reducing SSI after surgery compared to a single (preoperative) dose.
- Discontinuation of SAP after surgery avoids unnecessary extra costs, potential side-effects and <u>emergence of AMR.</u>

Practical points



- This recommendation is applicable to the peri- and postoperative periods.
- A relevant harm linked to SAP prolongation is the intestinal spread of *Clostridium difficile*, with higher risk of clinical manifestation of infection.
- It can be challenging to ensure SAP is not continued or confused with the need for antibiotics due to an infection.



http://www.who.int/infection-prevention/tools/focus-amr/en/

WHO conditional recommendations for SSI prevention



Conditional recommendations are also important recommendations for which the expert panel considered that the benefits of intervention probably outweighs the risks; however, when considering them for adoption, a more structured decision-making process should be undertaken, based on stakeholder consultation and involvement of patients and health care professionals.

This involves considering local priorities for improvement, feasibility, resource (both human and financial) implications and local culture.

WHO conditional recommendations for SSI prevention – preoperative period (1)



Торіс	Research question	Recommendation	<u>Strength</u> Quality
Perioperative discontinuation of immunosuppressive agents	Should immunosuppressive agents be discontinued perioperatively and does this affect the incidence of SSI?	Immunosuppressive medication should not be discontinued prior to surgery for the purpose of preventing SSI.	Conditional recommendation Very low quality of evidence
Enhanced nutritional support	In surgical patients, should enhanced nutritional support be used for the prevention of SSI?	Consider the administration of oral or enteral multiple nutrient-enhanced nutritional formulas for the purpose of preventing SSI in underweight patients who undergo major surgical operations.	Conditional recommendation Very low quality of evidence
Preoperative bathing	 Is preoperative bathing using an antiseptic soap more effective in reducing the incidence of SSI in surgical patients when compared to bathing with plain soap? Is preoperative bathing with CHG-impregnated cloths more effective in reducing the incidence of SSI in surgical patients when compared to bathing with antiseptic soap? 	It is good clinical practice for patients to bathe or shower before surgery. Either a plain soap or an antiseptic soap could be used for this purpose. Due to very low quality evidence, the panel decided not to formulate a recommendation the use of CHG- impregnated cloths for the purpose of reducing SSI.	Conditional recommendation Moderate quality of evidence

Source: Global guidelines for the prevention of surgical site infection. Geneva: World Health Organization; 2016 (<u>http://www.who.int/infection-prevention/publications/ssi-prevention-guidelines/en/).</u>

WHO conditional recommendations for SSI prevention – preoperative period (2)



Topic	Research question	Recommendation	<u>Strength</u> Quality
Decolonisation with mupirocin ointment with or without CHG body wash for the prevention of <i>S.</i> <i>aureus</i> infection in nasal carriers undergoing surgery	Is mupirocin nasal ointment in combination with or without a CHG body wash effective in reducing the number of <i>S. aureus</i> infections in nasal carriers undergoing surgery?	Patients undergoing cardiothoracic and orthopaedic surgery with known nasal carriage of <i>S. aureus</i> should receive perioperative intranasal applications of mupirocin 2% ointment with or without a combination of CHG body wash. Consider also treating patients with known nasal carriage of <i>S. aureus</i> undergoing other types of surgery with perioperative intranasal applications of mupirocin 2% ointment with or without a combination of CHG body wash.	Strong recommendation Moderate quality of evidence Conditional recommendation Moderate quality of evidence
MBP and the use of oral antibiotics	Is MBP combined with or without oral antibiotics effective for the prevention of SSI in colorectal surgery?	Preoperative oral antibiotics combined with MBP should be used to reduce the risk of SSI in adult patients undergoing elective colorectal surgery. MBP alone (without the administration of oral antibiotics) should not be used for the purpose of reducing SSI in adult patients undergoing elective colorectal surgery.	Conditional recommendation Moderate quality of evidence Strong recommendation Moderate quality of evidence

WHO conditional recommendations for SSI prevention – preoperative period (3)



Торіс	Research question	Recommendation	<u>Strength</u> Quality
Antimicrobial skin sealants	In surgical patients, should antimicrobial sealants (in addition to standard surgical site skin preparation) versus standard surgical site skin preparation be used for the prevention of SSI?	Antimicrobial sealants should not be used after surgical site skin preparation for the purpose of reducing SSI.	Conditional recommendation Very low quality of evidence
Perioperative oxygenation	How safe and effective is the perioperative use of an increased fraction of inspired oxygen in reducing the risk of SSI?	The panel suggests that adult patients undergoing general anaesthesia with endotracheal intubation for surgical procedures should receive an 80% fraction of inspired oxygen intraoperatively and, if feasible, in the immediate postoperative period for 2-6 hours to reduce the risk of SSI.	Conditional recommendation Moderate quality of evidence

WHO conditional recommendations for SSI prevention – intraoperative period (1)



Торіс	Research question	Recommendation	<u>Strength</u> Quality
Maintaining normal body temperature (normothermia)	In surgical patients, should systemic body warming versus no warming be used for the prevention of SSI?	Warming devices should be used in the operating room and during the surgical procedure for patient body warming with the purpose of reducing SSI.	Conditional recommendation Moderate quality of evidence
Use of protocols for intensive perioperative blood glucose control	 Do protocols aiming to maintain optimal perioperative blood glucose levels reduce the risk of SSI? What are the optimal perioperative glucose target levels in diabetic and non- diabetic patients? 	Protocols for intensive perioperative blood glucose control should be used for both diabetic and non-diabetic adult patients undergoing surgical procedures.	Conditional recommendation Low quality of evidence
Maintenance of adequate circulating volume control/ normovolaemia	Does the use of specific fluid management strategies during surgery affect the incidence of SSI?	Goal-directed fluid therapy should be used intraoperatively for the purpose of the reduction of SSI.	Conditional recommendation Low quality of evidence

WHO conditional recommendations for SSI prevention – intraoperative period (2)



Торіс	Research question	Recommendation	<u>Strength</u> Quality
Drapes and gowns	 Is there a difference in SSI rates depending on the use of disposable non-woven drapes and gowns vs. reusable, woven drapes and gowns? Does changing drapes during operations affect the risk of SSI? Does the use of disposable adhesive incise drapes reduce the risk of SSI? 	Either sterile disposable non-woven or sterile reusable woven drapes and surgical gowns can be used during surgical operations for the purpose of preventing SSI. <u>Plastic adhesive incise drapes</u> with or without antimicrobial properties should <u>not</u> be used for the purpose of preventing SSI.	Conditional recommendation Moderate to very low quality of evidence Conditional recommendation Low to very low quality of evidence
Wound protector devices	Does the use of wound protector devices reduce the rate of SSI in open abdominal surgery?	Consider the use of wound protector devices in <u>clean-contaminated</u> , <u>contaminated and dirty abdominal</u> surgical procedures for the purpose of reducing the rate of SSI.	Conditional recommendation Very low quality of evidence

WHO conditional recommendations World Hea for SSI prevention – intraoperative period (3)

Торіс	Research question	Recommendation	<u>Strength</u> Quality
Incisional wound irrigation	Does intraoperative wound irrigation reduce the risk of SSI?	There is insufficient evidence to recommend for or against saline irrigation of incisional wounds for the purpose of preventing SSI. Consider the use of irrigation of the incisional wound with an <u>aqueous</u> <u>povidone iodine solution</u> before closure for the purpose of preventing SSI, particularly in <u>clean and clean-</u> <u>contaminated wounds</u> . Antibiotic incisional wound irrigation before closure should not be used for the purpose of preventing SSI.	Conditional recommendation Low quality of evidence Conditional recommendation Low quality of evidence Conditional recommendation Low quality of evidence
Prophylactic negative pressure wound therapy	Does prophylactic negative pressure wound therapy reduce the rate of SSI compared to the use of conventional dressings?	Prophylactic negative pressure wound therapy may be used on <u>primarily closed</u> <u>surgical incisions in high-risk wounds</u> and, taking resources into account, for the purpose of preventing SSI.	Conditional recommendation Low quality of evidence

WHO conditional recommendations for SSI prevention – intraoperative period (4)



Торіс	Research question	Recommendation	<u>Strength</u> Quality
Antimicrobial- coated sutures	Are antimicrobial-coated sutures effective to prevent SSI? If yes, when and how should they be used?	Triclosan-coated sutures may be used for the purpose of reducing the risk of SSI, independent of the type of surgery.	Conditional recommendation Moderate quality of evidence
Laminar flow ventilation systems in the context of operating room ventilation	 Is the use of laminar air flow in the operating room associated with the reduction of overall or deep SSI? Does the use of fans or cooling devices increase SSIs? Is natural ventilation an acceptable alternative to mechanical ventilation? 	Laminar airflow ventilation systems should not be used to reduce the risk of SSI for patients undergoing total arthroplasty surgery.	Conditional recommendation Low to very low quality of evidence

WHO conditional recommendations for SSI prevention – postoperative period



Торіс	Research Question	Recommendation	<u>Strength</u> Quality
Antimicrobial prophylaxis in the presence of a drain and optimal timing for wound drain removal	 In the presence of drains, does prolonged antibiotic prophylaxis prevent SSI? When using drains, how long should they be kept in place to minimise SSI as a complication? 	Perioperative surgical antibiotic prophylaxis should not be continued due to the presence of a wound drain for the purpose of preventing SSI. The wound drain should be removed when clinically indicated. No evidence was found to allow making a recommendation on the optimal timing of wound drain removal for the purpose of the prevention of SSI.	Conditional recommendation Low quality of evidence Conditional recommendation Very low quality of evidence
Advanced dressings	In surgical patients, should advanced dressings vs. standard sterile wound dressings be used for the prevention of SSI?	Advanced dressing of any type should <u>not</u> be used over a standard dressing on primarily closed surgical wounds for the purpose of preventing SSI.	Conditional recommendation Low quality of evidence

2014 systematic review & 2016 WHO guidelines

Results:

- 15 RCT, 7237 patients
- Range of procedures
- General & Neuraxial anesthesia
- OR: 0.84 (95% CI, 0.66 to 1.06)
- Chi² P-value: 0.01, I²: 51%

*See WHO Guidelines chapter 4.12 pages 110-115 and Web Appendix 13 at http://www.who.int/gpsc/appendix13.pdf?ua=1

2014 systematic review & 2016 WHO guidelines *Overall analysis*


15 RCT, 7237 patients Range of procedures General & Neuraxial anesthesia

1) Administration of increased FiO2 vs. standard oxygenation

-							
	Hypero		Normo			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Belda 2005	22	148	35	143	8.1%	0.54 [0.30, 0.97]	
Bickel 2011	6	107	14	103	4.2%	0.38 [0.14, 1.02]	
Duggal 2013	34	416	34	415	9.5%	1.00 [0.61, 1.64]	_ + _
Gardella 2008	17	69	10	74	5.2%	2.09 [0.88, 4.96]	—
Grief 2000	13	250	28	250	б.9%	0.43 [0.22, 0.86]	
Mayzler 2005	2	19	3	19	1.4%	0.63 [0.09, 4.26]	
Meyhoff 2009	131	685	141	701	13.4%	0.94 [0.72, 1.22]	-
Myles 2007	77	997	106	1015	12.6%	0.72 [0.53, 0.98]	
Pryor 2004	20	80	9	80	5.2%	2.63 [1.11, 6.20]	
Schietroma 2013	5	86	11	85	3.6%	0.42 [0.14, 1.25]	
Schietroma 2014	6	40	11	41	3.6%	0.48 [0.16, 1.46]	
Scifres 2011	35	288	26	297	8.9%	1.44 [0.84, 2.46]	+
Stall 2013	14	119	19	116	б.3%	0.68 [0.32, 1.43]	
Thibon 2012	15	226	15	208	б.3%	0.91 [0.44, 1.92]	
Williams 2013	10	77	12	83	4.9%	0.88 [0.36, 2.18]	
Total (95% CI)		3607		3630	100.0%	0.84 [0.66, 1.06]	•
Total events	407		474				
Heterogeneity: Tau ² =	0.09; Cł	ni ² = 28	3.31, df =	= 14 (P	= 0.01);	$l^2 = 51\%$	0.01 0.1 1 10 100
Test for overall effect:	Z = 1.47	'(P = 0	. 14)				0.01 0.1 1 10 100' Favours Hyperoxia Favours Normoxia
		-					ravours rigperoxia ravours normoxia

M-H: Mantel-Haenszel (test); CI: confidence interval

2014 systematic review & 2016 WHO guidelines *Overall analysis*



2014 systematic review & 2016 WHO guidelines *Sub-group analysis*

	Hyperoxia		Normo		Odds Ratio		Odds Ratio
Study or Subgroup					Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.2.1 General anesth	esia with	endot	racheal 1	tube			
Belda 2005	22	148	35	143	8.1%	0.54 [0.30, 0.97]	
Bickel 2011	б	107	14	103	4.2%	0.38 [0.14, 1.02]	
Grief 2000	13	250	28	250	6.9%	0.43 [0.22, 0.86]	
Mayzler 2005	2	19	3	19	1.4%	0.63 [0.09, 4.26]	
Meyhoff 2009	131	685	141	701	13.4%	0.94 [0.72, 1.22]	-
Myles 2007	77	997	106	1015	12.6%	0.72 [0.53, 0.98]	
Pryor 2004	20	80	9	80	5.2%	2.63 [1.11, 6.20]	
Schietroma 2013	5	86	11	85	3.6%	0.42 [0.14, 1.25]	
Schietroma 2014	б	40	11	41	3.6%	0.48 [0.16, 1.46]	
Stall 2013	14	119	19	116	6.3%	0.68 [0.32, 1.43]	
Thibon 2012	15	226	15	208	6.3%	0.91 [0.44, 1.92]	
Subtotal (95% CI)		2757		2761	71.6%	0.72 [0.55, 0.94]	◆
Total events	311		392				
Heterogeneity: Tau ² =	= 0.08; Ch	Heterogeneity: Tau ² = 0.08; Chi ² = 18.51, df = 10 (P = 0.05); l ² = 46%					
Test for overall effect:	Z = 2.44	(P = 0	.01)				
Test for overall effect: 1.2.7 Procedure under				otrache	al intuba	tion	
1.2.7 Procedure unde					al intuba 9.5%		
1.2.7 Procedure unde Duggal 2013	er neurox	ia with	out end		9.5%	1.00 [0.61, 1.64]	
1.2.7 Procedure unde	er neurox 34	ia with 416	out end 34	415 74		1.00 [0.61, 1.64] 2.09 [0.88, 4.96]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008	er neurox 34 17	ia with 416 69	out end 34 10	415 74	9.5% 5.2%	1.00 [0.61, 1.64]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011	er neurox 34 17 35	ia with 416 69 288	out end 34 10 26	415 74 297	9.5% 5.2% 8.9%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013	er neurox 34 17 35	ia with 416 69 288 77	out end 34 10 26	415 74 297 83	9.5% 5.2% 8.9% 4.9%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI)	er neurox 34 17 35 10 96	ia with 416 69 288 77 850	out end 34 10 26 12 82	415 74 297 83 869	9.5% 5.2% 8.9% 4.9% 28.4%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI) Total events	er neurox 34 17 35 10 96 = 0.00; Ch	ia with 416 69 288 77 850 ii ² = 3.1	out end 34 10 26 12 82 00, df =	415 74 297 83 869	9.5% 5.2% 8.9% 4.9% 28.4%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	er neurox 34 17 35 10 96 = 0.00; Ch	ia with 416 69 288 77 850 hi ² = 3. 0 (P = 0	out end 34 10 26 12 82 00, df =	415 74 297 83 869 3 (P =	9.5% 5.2% 8.9% 4.9% 28.4% 0.39); I ²	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69] = 0%	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	er neurox 34 17 35 10 96 = 0.00; Ch : Z = 1.30	ia with 416 69 288 77 850 ii ² = 3.1	out end 34 10 26 12 82 00, df = .19)	415 74 297 83 869 3 (P =	9.5% 5.2% 8.9% 4.9% 28.4%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Total events	er neurox 34 17 35 10 96 = 0.00; Ch : Z = 1.30 407	ia with 416 69 288 77 850 hi ² = 3.0 (P = 0 3607	out end 34 10 26 12 82 00, df = .19) 474	415 74 297 83 869 3 (P = 3630	9.5% 5.2% 8.9% 4.9% 28.4% 0.39); l ² 100.0%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69] = 0% 0.84 [0.66, 1.06]	
1.2.7 Procedure unde Duggal 2013 Gardella 2008 Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	er neurox 34 17 35 10 96 = 0.00; Ch : Z = 1.30 407 = 0.09; Ch	ia with 416 69 288 77 850 1i ² = 3.0 (P = 0 3607 1i ² = 28	out end 34 10 26 12 82 00, df = .19) 474 3.31, df =	415 74 297 83 869 3 (P = 3630	9.5% 5.2% 8.9% 4.9% 28.4% 0.39); l ² 100.0%	1.00 [0.61, 1.64] 2.09 [0.88, 4.96] 1.44 [0.84, 2.46] 0.88 [0.36, 2.18] 1.23 [0.90, 1.69] = 0% 0.84 [0.66, 1.06]	.01 0.1 10 10 Favours Hyperoxia Favours Normoxia

2014 systematic review & 2016 WHO guidelines Sub-group analysis

General anest. + endotr. intub.

Neuraxial. anest. vs endotr. intub


Subtotal (95% C)	27	57	2761	71.6%	0.72 [0.55, 0.94]
Total events	3	11	39	92		
Heterogeneity, Ta	$4u^2 = 0.08$	3; Chi ² =	18.51.0	df = 10 (P	$= 0.05$); $ ^2$	= 46%
Test for overall et		,	,	,	.,	
Schietroma 2013	5 86	11 85	3.6% 0.	.42 [0.14, 1.25]	•	
Subtotal (95% CI)	85	0	869	28.4%	1.23 [0.90, 1.69]
Total events		96	8	32		
Heterogeneity: Ta			-		$1.391 \cdot 1^2 = 0$	*
Test for overall ef		-		- 5 (r - 1	0.39), 1 = 0	/0
resciol overall er	ect. 2 = 1	L. S V (F =	0.19)			
Gardella 2008	17 69	10 /4	5.2% 2.	.09 [0.88, 4.96]		
Scifres 2011	35 288 10 77	26 297 12 83		.44 [0.84, 2.46]	_	
Scifres 2011 Williams 2013 Subtotal (95% CI)	10 77 850	12 83 869	4.9% 0.		-	•
Scifres 2011 Williams 2013 Subtotal (95% CI) Total events	10 77 850 96	12 83 869 82	4.9% 0. 28.4% 1	.44 [0.84, 2.46] .88 [0.36, 2.18]	-	•
Scifres 2011 Williams 2013 Subtotal (95% CI)	10 77 850 96 0.00; Chi ² = 3.00	12 83 869 82 , df = 3 (P = 0	4.9% 0. 28.4% 1	.44 [0.84, 2.46] .88 [0.36, 2.18]	-	•
Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity. Tau ² =	10 77 850 96 0.00; Chi ² = 3.00	12 83 869 82 , df = 3 (P = 0	4.9% 0. 28.4% 1 .39); I ² = 0%	.44 [0.84, 2.46] .88 [0.36, 2.18]	_	•
Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity. Tau ² = Test for overall effect: 2 Total (95% CI) Total events	10 77 850 96 0.00; Chi ² = 3.00; Z = 1.30 (P = 0.1; 3607 407	12 83 869 82 , df = 3 (P = 0 9) 3630 474	$\begin{array}{ccc} 4.9\% & 0.\\ 28.4\% & 1\\ .39); \ ^2 = 0\% \\ 100.0\% & 0 \end{array}$.44 [0.84, 2.46] .88 [0.36, 2.18] 1.23 [0.90, 1.69] 0.84 [0.66, 1.06]	-	•
Scifres 2011 Williams 2013 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 2 Total (95% CI)	10 77 850 96 0.00; Chi ² = 3.00, 2 = 1.30 (P = 0.1; 3607 407 0.09; Chi ² = 28.3 Z = 1.47 (P = 0.1;	12 83 869 82 , df = 3 (P = 0 9) 3630 474 1, df = 14 (P = 4)	$\begin{array}{c} 4.9\% & 0,\\ \mathbf{28.4\%} & 1 \\$.44 [0.84, 2.46] .88 [0.36, 2.18] 1.23 [0.90, 1.69] 0.84 [0.66, 1.06]		tio 100 xia Favours Normoxia

2014 systematic review & 2016 WHO guidelines

<u>WHO recommendation:</u> "The panel recommends that adult patients undergoing general anaesthesia with endotracheal intubation for surgical procedures should receive an 80% fraction of inspired oxygen intraoperatively and, if feasible, in the immediate postoperative period for 2-6 hours to reduce the risk of SSI."

Recommendation: Strong

Quality of evidence: Moderate



Concerns raised & GDG consultation 1 (first semester 2017)

*Jannicke Mellin-Olsen, Robert J McDougall, Davy Cheng Jannicke@mellin.no

World Federation of Societies of Anaesthesiologists (JM-0, RJM, DC); Department

EDITORIAL VIEWS

Who Can Make Sense of the Surgical Site Infection?

Göran Hedenstierna, M.D., Ph.D., Gaetano P€

The New World Health Organiza on Perioperative Administratio Surgical Site Infections: A Dan Approach?

Manuel Wenk, MD, PhD, Hugo Van Aken, MD, PhD, and Al

*Christian S Meyhoff, Siv Fonnes, Jørn Wetterslev, Lars N Jorgensen, Lars S Rasmussen

Editorial

Anaesthesist DOI 10.1007/s00101-017-0286-4

© Springer Medizin Verlag GmbH 2017

CrossMark

T. Volk¹ • J. Peters² • D. I. Sessler³ ¹ Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany

² Klinik f
ür An
ästhesiologie und Intensivmedizin, Universit
ät Duisburg-Essen & Universit
ätsklinikum Essen, Essen, Germany

³ Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, USA

Turk J Anaesthesiol Reanim 2017; 45: 181-92

DOI: 10.5152/TJAR.2017.25070



WHO Needs High FIO₂?

Ozan Akca¹, Lorenzo Ball², F. Javier Belda³, Peter Biro⁴, Andrea Cortegiani⁵, Arieh Eden⁶, Carlos Ferrando³, Luciano Gattinoni⁷, Zeev Goldik⁶, Cesare Gregoretti⁵, Thomas Hachenberg⁸, Göran Hedenstierna⁹, Harriet W. Hopf¹⁰, Thomas K. Hunt¹¹, Paolo Pelosi², Motaz Qadan¹², Daniel I. Sessler¹³, Marina Soro³, Mert Şentürk¹⁴

In October 2016, the World Health Organization (WHO) ing surgical site infections (SSIs). Among those measu oxygen at an inspired fraction of 80% intra- and postc.

been identified as global health problem, and the WHO should be commended for their efforts. However, this recommendation focuses only on the patient's "wound," ignores other organ systems potentially affected by hyperoxia, and may ultimately worsen patient outcomes. The WHO advances a "strong recommendation" for the use of a high inspired oxygen fraction even though the quality of evidence is only moderate. However, achieving this goal by disregarding other potentially lethal complications seems inappropriate, particularly in light of the weak evidence underpinning the use of high fractions of oxygen to prevent SSI. Use of such a strategy thus should be intensely discussed by anesthesiologists and perioperative physicians. Normovolemia, normotension, normoglycemia, normothermia, and normoventilation can clearly be orfeited applied to ment extent to ment elicitical generative. But the libration application of

Phase#2: Concerns raised & GDG consultation 1 (first semester 2017)

- Effectiveness of the use of high FiO2
 - Sub-group analysis
 - Update 2015
 - Inclusion criteria
- Harms of the use of high FiO2
 - Atelectasis
 - Animal experiments
 - Other clinical settings (i.e. respiratory distress, critically ill)
- Resource use of the use of high FiO2
 - Priority



ARTICLE IN PRESS

BJA

British Journal of Anaesthesia, xxx (xxx): xxx (xxxx) BIA doi: 10.1016/j.bja.2018.11.026 Advance Access Publication Date: xxx **Review Article**

British Journal of Anaesthesia, xxx (xxx): xxx (xxxx)

doi: 10.1016/j.bja.2018.11.024 Advance Access Publication Date: xxx **Review Article**

REVIEW ARTICLE

Safety of 80% vs 30-35% fraction of inspired oxygen in patients undergoing surgery: a systematic review and meta-analysis

Katharina Mattishent¹, Menaka Thavarajah¹, Ashnish Sinha¹, Adam Peel¹, Matthias Egger², Joseph Solomkin³, Stijn de Jonge⁴, Asad Latif^{5,6}, Sean Berenholtz^{5,6}, Benedetta Allegranzi^{7,*} and Yoon Kong Loke¹

¹Norwich Medical School, University of East Anglia, Norwich, UK, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA, ⁴Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam Infection and Immunity, Amsterdam UMC, Location AMC, University of Amsterdam, the Netherlands, ⁵Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School ⁷Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA of Medicine, Baltimore, MD, USA, ⁶Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, USA and ⁷Infection Prevention and Control Global Unit, Service Delivery and Safety, World Health Organization, Geneva, Switzerland

*Corresponding author. E-mail: allegranzib@who.int

Effectiveness of 80% vs 30-35% fraction of inspired oxygen in patients undergoing surgery: an updated systematic review and meta-analysis

Stijn de Jonge¹, Matthias Egger², Asad Latif^{3,4}, Yoon Kong Loke⁵, Sean Berenholtz^{3,4}, Marja Boermeester¹, Benedetta Allegranzi^{6,*,†} and Joseph Solomkin^{7,†}

¹Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam Infection and Immunity, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, ⁴Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, USA, ⁵Norwich Medical School, University of East Anglia, Norwich, UK, ⁶Infection Prevention and Control Global Unit, Service Delivery and Safety, World Health Organization, Geneva, Switzerland and

*Corresponding author. E-mail: allegranzib@who.int [†]These authors contributed equally to the manuscript

de Jonge et al. Br J Anaesth. 2019 Mar;122(3):325-334 Mattishent et al. Br J Anaesth. 2019 Mar;122(3):311-324

Final updated evidence on effectiveness (July 2018)

- Six new trials identified
- Retraction Schietroma trial & serious concerns on other 3 trials validity
 - => Exclude all 4 from primary analysis.

 Overall analysis: 	RR: 0.89 (95%Cl, 0.73, 1.07)
 Meta regression anesthesia 	P-value: 0.048
 Subgroup general anesthesia: 	RR: 0.80 (95%Cl, 0.64, 0.99)
 Subgroup neuraxial anesthesia: 	RR: 1.20 (95%Cl, 0.91, 1.58)


- No further evidence of effect modification
- NB: Sensitivity and meta-regression analyses of Schietroma papers; significant influence effect estimate

Final updated evidence on effectiveness (July 2018)

	2014 SR & Meta analysis	2018 SR & Meta analysis
General result	15 RCTs, 7237 participants	17 RCTs, 7817 participants
Schietroma et al.	1 Retracted, 1 Under investigation	All disputed trials excluded
Overall estimate:	OR: 0.84 (95% CI, 0.66, 1.06)	RR: 0.89 (95%Cl, 0.73, 1.07)
Heterogeneity:	Chi ² P value: 0.01 , I2: 51%	Chi2 P value: 0.02 , I2: 46%
Meta regression anesthesia	P value= 0.05	P value = 0.048
Subgroup general anesthesia	OR: 0.72 (95%Cl, 0.55, 0.94)	RR: 0.80 (95%Cl, 0.64, 0.99)
Subgroup neuraxial anesthesia	OR: 1.23 (95%Cl, 0.90, 1.69)	RR: 1.20 (95%Cl, 0.91, 1.58)

*Evidence quality (GRADE): moderate quality of evidence





Our meta-analysis of several important outcomes did not demonstrate any definite signal of harm with 80% FiO₂ inspired oxygen. There is no substantive evidence of safety concerns that would go against implementation of the WHO and Centers for Disease Control and Prevention recommendations on the use of high FiO₂ to reduce SSI in intubated patients undergoing surgical procedures.

83/030

96/911

Subtotal (I2=0.0%, P=0.482) 1.20 (0.91, 1.58) Conclusions: The WHO updated analyses did not show definite beneficial effect of the use of high perioperative FiO₂, overall, but there was evidence of effect of reducing the SSI risk in surgical patients under general anaesthesia with tracheal intubation. However, the evidence for this beneficial effect has become weaker and the strength of the recommendation needs to be reconsidered.

Chen and colleagues (2013)

Stall and colleagues (2013) Kurz and colleagues (2015)

Wasnik and colleagues (2015)

Subtotal (I2=46.7%, P=0.043)

Gardella and colleagues (2008)

Scifres and colleagues (2011) Duggal and colleagues (2013)

Williams and colleagues (2013) Fariba and colleagues (2016)

Oxygen administered via a face mask without intubation

de Jonge et al. Br J Anaesth. 2019 Mar;122(3):325-334 Mattishent et al. Br J Anaesth. 2019 Mar;122(3):311-324

Final updated evidence on safety*

2018	SR 8	، Meta	ana	lysis
------	------	--------	-----	-------

General 27 studies: 17 RCTs, 8 post hoc / subgroup analysis, 2 non-randomized studies

	RCT (good quality, poor AE definition)	Non-RCT (Critical – Serious risk of bias)
Atelectasis	RR: 0.91 (95%Cl, 0.59 - 1.42), I ² : 85%	NA
Pneumonia	RR: 0.78 (95%Cl, 0.50 - 1.09), I ² : 29%	OR: 1.72 (95%Cl, 1.30 – 2.28)
Respiratory AE	NA SdJ5	OR: 1.99 (95%Cl, 1.72 – 2.31)
ICU admission	RR: 0.93 (95%Cl, 0.70 - 1.12), I ² : 03%	OR: 1.64 (95%Cl, 1.38 – 1.95)
Cardiovasc AE	RR: 0.90 (95%Cl, 0.32 - 2.54), I ² : 58%	OR: 0.90 (95%Cl, 0.32 – 2.54)
TE	RR: 0.89 (95%Cl, 0.28 – 2.91) l ² : 74%	NA
Short term +•	RR: 0.49 (95%Cl, 0.17 – 1.37) l ² : 50%	OR: 2.09 (95%Cl, 0.81 – 5.43)
Long term †	RR: 0.96 (95%Cl, 0.65 – 1.42) l ² : 55%	OR: 1.97 (95%Cl, 1.30 – 2.99), RR: 1.97 (95%Cl, 0.71 – 5.47)

*Evidence quality (GRADE): from very low to moderate; overall low quality of evidence

SdJ5 Not pooled due to variation in case definition, but two RCTs with both no evidence of significant harm. Stijn de Jonge; 10.10.2018

Conclusions

- Exclusion of four studies with disputed credibility and net addition of four new trials.
- Additional information <u>did not strengthen</u> the evidence for <u>effect modification</u> found in the original review and the evidence for a <u>benefit in patients</u> <u>undergoing general anaesthesia with endotracheal</u> <u>intubation</u> that led to the strong recommendation in the WHO guidelines.
- Evidence for a beneficial effect has become weaker despite increased number of patients.
- The benefits of hyperoxygenation would likely be maximized when normothermia and normovolemia are maintained
- Evidence supporting safety has become stronger: no definite signal of harm and no or little evidence to discourage the use of high FiO₂ in this population.
- Further high-quality RCTs are urgently needed.

WHO Guidelines Development Group

The chair of the Guidelines Development Group was Joseph S Solomkin (University of Cincinnati College of Medicine/OASIS Global, USA).

The GRADE methodologist of the WHO Guidelines Development Group was Matthias Egger (University of Bern, Bern, Switzerland).

The following experts served on the Guidelines Development Group:

Hanan H Balkhy (King Saud Bin Abdulaziz University for Health Sciences, Kingdom of Saudi Arabia); Javier F Belda (University of Valencia, Spain); Sean Berenholtz (Johns Hopkins Medicine, Baltimore, USA); Marja A Boermeester (University of Amsterdam, the Netherlands); Nizam Damani (Craigavon Area Hospital, UK); E Patchen Dellinger (University of Washington, USA); Mazen S Ferwana (King Saud Bin Abdulaziz University for Health Sciences, Kingdom of Saudi Arabia); Petra Gastmeier (Institute of Hygiene and Environmental Medicine, Charité-University Medicine Berlin, Germany); Robert Greif (Hospital University of Bern, Switzerland); Asad Latif (Johns Hopkins Medicine, Baltimore, USA); Xavier Guirao (Parc Taulí Hospital Universitari, Spain); Nordiah Jalil (University Kebangsaan Malaysia Medical Centre, Malaysia); Robinah Kaitiritimba (Uganda National Health Consumers' Organization, Uganda); Fauzia Khan (Aga Khan University Karachi, Pakistan); Janet Martin (School of Medecine/Dentistry Western University, Ontario, Canada); Regina Kamoga (Community Health and Information Network, Uganda); Claire Kilpatrick (KS Healthcare Consulting (S3 Global, UK); Shaheen Mehtar (Stellenbosch University and Infection Control Africa Network, Republic of South Africa); Jannicke Mellin-Olsen (World Federation of Societies of Anesthesiologists, London, UK); Babacar Ndoye (Infection Control Africa Network Board, Senegal); Peter Nthumba (AIC Kijabe Hospital, Kenya); Bisola Onajin Obembe (University of Port Harcourt,

Nigeria); Akca Ozan (University of Louisville, USA); Leonardo Pagani (Bolzano Central Hospital, Italy); Didier Pittet (University of Geneva Hospitals, Switzerland); Jianan Ren (Nanjing University, People's Republic of China); Joseph S Solomkin (University of Cincinnati, USA); Akeau Unahalekhaka (Chiang Mai University, Thailand); Andreas F Widmer (Basel University, Switzerland).








Translating guidelines to action












- Document presenting a range of *tested approaches to achieve successful SSI prevention*implementation at the facility level,
 including in the context of a broader
 surgical safety climate
 - Original section on the surgical safety checklist use worldwide
 - Results of a comprehensive systematic review on SSI prevention strategies
 - Section on WHO pilot testing through the SUSP study

http://www.who.int/infection-prevention/tools/surgical/en/ Ariyo P, et al. ICHE 2019 Feb 21:1-14. doi: 10.1017/ice.2018.355





Operational manual for the WHO SSI prevention recommendations.

This implementation manual is designed to be used by all persons concerned by the prevention of SSI in all health care settings, irrespective of the country.

Launched in December 2018

http://www.who.int/infection-prevention/tools/surgical/en/




Technical Work

Evidence-based interventions

Adaptive Work

Safety culture





Pilot testing the approach

across all sites, available implementation support documents, and process indicators used.

on a monthly basis between the baseline and follow-up periods by site (four sites).

measures implemented during the study intervention period.

prevention/countries/surgical/en/ (accessed Feb 19, 2018).

prevention/countries/surgical/en/ (accessed Feb 19, 2018).

prevention/countries/surgical/en/ (accessed Feb 19, 2018).

the three study periods for each site.

Figure S1: Poster/leaflet designed by the surgical teams to remind staff of the surgical site infection prevention

Figure S2: Trends of the cumulative incidence of surgical site infection per 100 surgical operations by month in

Figure S3: Results of an interrupted time series analysis assessing the trends of the cumulative incidence of SSI

Figure S4: Results of an interrupted time series analysis assessing the trends of cumulative incidence of surgical

site infection on a monthly basis between the follow-up and sustainability periods by site (three sites).

Fact sheet S2: Surgical site skin preparation and surgical hand preparation. http://www.who.int/infection-

Fact sheet S1: Patient preparation: bathing and hair removal. http://www.who.int/infection-

Fact sheet S3: Correct and safe surgical antibiotic prophylaxis. http://www.who.int/infection-

Articles




A multimodal infection control and patient safety @* intervention to reduce surgical site infections in Africa: a multicentre, before-after, cohort study

Benedatta Allegranzi, Alexander M Aiken, Nejia Zeynep Kubilay, Pet er Nthumba, Jack Barasa, Gabriel Okumu, Robert Mugarura, Nexander Elobu, Josephat Jombwe, Mayaba Maimbo, Joseph Musowoya, Angèle Gayet-Ageron, Sean M Berenhol tz

Contents

Background Surgical site infections (SSIs) are the most frequent health-care-associated infections in developing (another store 2018); countries. Specific prevention measures are highly effective, but are often poorly implemented. We aimed to 18:597-45 establish the effect of a multimodal intervention on SSIs in Africa.



891 in the sustainability period). SSI 8.0% (95% CI 6.8-9.5; n=129) to 3.8% period (3.9%, 2.8-5.4; n=35). A substar served in the follow-up and sustainal than pre-intervention (odds ratio [OR] significantly reduced (0.72, 0.42-1.24;

Interpretation Implementation of our across all perioperative prevention practi heterogeneity between sites. Further las improve the sustainability and long-term

Funding US Agency for Healthcare Resea

Copyright © 2018. World Health Organ

Introduction

Health-care-associated infections are common adverse events during care evidence exists on the morbidity, mortal health-care-associated infections in l middle-income countries, but WHO es that the overall prevalence in these cou the average reported in high-incom According to WHO, surgical site infect most surveyed and most frequent health infection in countries of low and middle affect up to one-third of surgical significantly increased risk of SSI in cour middle income affects all types of proce clean surgery.2 SSI is also the second health-care-associated infection in Europ Given the increasing recognition of the

www.thelancet.com/neurology Vol 17 May 2018



uv NE UT CO ĸs NM

195 Hospitals



Allegranzi B, et al. Lancet Infect Dis. 2018 May;18(5):507-515. doi: 10.1016/S1473-3099(18)30107-5 Clack L, et al. Antimicrob Resist & Infect Control, submitted



Pilot testing the approach

Articles



A multimodal infection con intervention to reduce surgi a multicentre, before–after,-	ical site infections i		Constant	And Conception	South Sudar Upinda Nerry Somalia
Benedett a Allegranzi, Alacander M Aiken, Nejla Zeynep Ku bilay, F Nexander Elobu, Josephat Jombwe, Mayaba Maimbo, Joseph Ma		Hospital type	Setting	Intervention implementation activities common to all sites	Additional activities
Summary Background Surgical site infections (SSIs) are the countries. Specific prevention measures are high establish the effect of a multimodal intervention on Methods We did a before-after cohort study, betwee multimodal intervention consisted of the implement combined with an adaptive approach aimed at the is outcome was the first occurrence of SSI, and the sec adherence to SSI prevention measures were prospe within 30 days post surgery was assessed in a mit confounders.	Kijabe AIC Hospital, Kenya	Private, mission hospital, 360 beds	Rural	Technical SSI preventive measures*: patient preoperative bathing with plain or antiseptic soap; appropriate hair removal (avoidance of or using clippers); optimise patient skin preparation, including local production of alcohol-based and chlorhexidine-based skin disinfection product; optimise surgical hand preparation, including local production of alcohol-based hand rub product and appropriate rubbing technique; appropriate antibiotic prophylaxis based on locally formulated policy, given within 1-h preoperatively and discontinued postoperatively; improved operating theatre discipline, including limitation of the number of individuals and reduction of intraoperative movement. Adaptive (team-working and safety) elements†: formation of local SUSP perioperative team; engagement of surgical leads and senior executives; patient safety culture survey; patient safety video played by local surgical leaders; use of CUSP adaptive tools, including Staff safety assessment and Learning from defects; morbidity and mortality meetings; foodback of date on SCI surveillance and compliance with the SCI persurvation	Provision of antiseptic soap to patients for bathing; addition of food dye to alcohol-based skin preparation to aid visualisation of the application area around the incision site; leaflets explaining the intervention
Findings Four hospitals completed the baseline and quality) data for the sustainability period. 4322 oper 391 in the sustainability period. 551 cumulativ 8-0% (55% CI 6-8-9:5; p=129) 103-3% (3-0-4.3; n period (3-3%, 2-8-5; +123) A substantial improve observed in the follow-up and sustainability periods. than pre-intervention (old ratio [OR] 0-40, 55% (significantly reduced (0-72, 0-42-1-24; p=0-2560). Interpretation Implementation of our intervention across all perioperative prevention practices. A signifi- heterogeneity between sites. Further Large-scale exp	Mulago Hospital, Uganda	Public sector, tertiary referral, 1500 beds	Urban		Better management of students to reduce crowding in operating theatres; work with hospital pharmacy to ensure an antibiotic supply for surgical prophylaxis; patient information card on surveillance in English and local language
improve the sustainability and long-term effect of as Funding US Agency for Healthcare Research and Qe Copyright © 2015. World Health Organization. Pub Introduction Health-care-associated infections are one of the r common adverse events during care delivery. ¹ I	Kisiizi Hospital, Uganda	Private, mission hospital, 260 beds	Rural		New locks and lockers in operating theatres to minimise staff movement during operations
evidence exists on the morbidity, mortality, and effer health-care-associated infections in low-income middle-income countries, but WHO estimates indi that the overall prevalence in these countries is do the average reported in high-income countri According to WHO, surgical site infection (SSI) is most surveyed and most frequent health-care-associ infection in countries of low and middle income, and affect up to one-third of surgical patients.	Ndola Hospital, Zambia	Public sector, tertiary referral, 851 beds	Urban	feedback of data on SSI surveillance and compliance with the SSI preventive measures, including SSI rates.	Better management of students to reduce crowding in operating theatres

middle income affects all types of procedure, indus **Figure 1**: Characteristics of the four participating hospitals and activities implemented during the intervention clean supery Sti is also the second most come

health-care-associated infection in Europe and the US Due to unforeseen local difficulties, one site (Zimbabwe) was unable to recruit adequate numbers of patients and was not included in the analysis. SSI=surgical site infection. SUSP=Surgical Unit-based Safety Programme. CUSP=Comprehensive Unit-based Safety Programme. *Support materials related to the technical SSI preventive measures are available at http://www.who-int/infection-prevention/countries/surgical/en/ (see appendix). †Materials from the CUSP study used in this project are available at https://www.ahrq.gov/professionals/quality-patient-safety/hais/tools/surgery/index.html.

Allegranzi B, et al. Lancet Infect Dis. 2018 May;18(5):507-515. doi: 10.1016/S1473-3099(18)30107-5 Clack L, et al. Antimicrob Resist & Infect Control, submitted

ww.thelancet.com/neurology Vol 17 May 2018



Example adaptive tools – addressing the culture



CUSP for Safe Surgery Perioperative Staff Safety Assessment

Purpose of this form: The purpose of this form is to tap into your experiences at the frontlines of patient care to find out what risks jeopardize patient safety in your clinical area.

Who should complete this form: All staff members.

How to complete this form: Provide as much detail as possible when answering the 4 questions. Drop off your completed safety assessment form in the location designated by the SUSP team.

When to complete this form: Any staff member can complete this form at any time.

CUSP for Safe Surgery (SUSP) Safety Issues Worksheet for Senior Executive Partnership

Date of Safety Rounds:		
Unit:		
Attendees:		
1.	5.	
2.	6.	
3.	7.	
4.	(Please use back of form for additional attendees.)	

CUSP for Safe Surgery (SUSP) Executive Safety Rounds Kickoff Template

The Learning From Defects Tool





Armstrong Institute for Patient Safety and C





Armstrong Institute for Patient Safety and Quality

Impact on preventive measures




Baseline (n=1604)	Follow-up (n=1827)	p value	Sustainability period (n=891)
1238 (77-2)	1544 (84-5)	<0.0001	799 (89.7)
1169 (73-1)	1702 (93.5)	<0.0001	880 (98.8)
330 (20.7)	1644 (90-2)	<0.0001	845 (94-8)
1213 (78-7)	1694 (94·4)	<0.0001	865 (97-4)
205 (12.8)	714 (39·1)	<0.0001	635 (71·3)
14.8 (17.8)	14.2 (16.1)	0.3771	19.0 (21.6)
8-3 (3-4)	7.7 (2.5)	<0.0001	7.4 (2.5)
5.0 (4.1)	4.8 (4.9)	0.1758	4.2 (2.7)
	(n=1604) 1238 (77·2) 1169 (73·1) 330 (20·7) 1213 (78·7) 205 (12·8) 14·8 (17·8) 8·3 (3·4)	(n=1604) (n=1827) 1238 (77·2) 1544 (84·5) 1169 (73·1) 1702 (93·5) 330 (20·7) 1644 (90·2) 1213 (78·7) 1694 (94·4) 205 (12·8) 714 (39·1) 14·8 (17·8) 14·2 (16·1) 8·3 (3·4) 7·7 (2·5)	(n=1604)(n=1827) $1238 (77.2)$ $1544 (84.5)$ <0.0001


Data are mean (SD). Data per variable and percentage missing data are also given. SSI-surgical site infection.

Table 2: Process indicators for SSI prevention intervention measures across study periods in four (baseline and follow-up) and three (sustainability period) hospitals









Summary of success factors for SSI prevention implementation



- Use of multimodal strategies
- Having a dedicated multidisciplinary team and a step-wise action plan
- Mapping recommendations according to the surgical patient journey
- Empowering teams involving front-line staff and letting teams take the lead on adaptation
- Engaging leadership
- Catalysing collective and individual ownership
- Using data to create awareness
- Awarding teams and work demonstrating a safety culture spirit

Allegranzi B, et al. *Lancet Infect Dis.* 2018 May;18(5):507-515. doi: 10.1016/S1473-3099(18)30107-5 Clack L, et al. *Antimicrob Resist & Infect Control*, submitted

IPC improvement strategy: multimodal thinking



Multidisciplinary team

In other words, the WHO multimodal improvement strategy addresses these five areas:

> 2. Teach it (training & education)

Who needs to be trained? What type of training should be used to ensure that the intervention will be implemented in line with evidence-based policies and how frequently?

Does the facility have trainers, training aids, and the necessary equipment?

Practical example: when implementing injection safety interventions, timely training of those responsible for administering safe injections, including carers and community workers, are important considerations, as well as adequate disposal methods.

> 4. Sell it (reminders & communications)

How are you promoting an intervention to ensure that there are cues to action at the point of care and messages are reinforced to health workers and patients?

Do you have capacity/funding to develop promotional messages and materials?

Practical example: when implementing interventions to reduce catheter-associated bloodstream infection, the use of visual cues to action, promotional/reinforcing messages, and planning for periodic campaigns are important considerations.





What infrastructures, equipment, supplies and other resources (including human) are required to implement the intervention?

Does the physical environment influence health worker behaviour? How can ergonomics and human factors approaches facilitate adoption of the intervention?

Are certain types of health workers needed to implement the intervention?

Practical example: when implementing hand hygiene interventions, ease of access to handrubs at the point of care and the availability of WASH infrastructures (including water and soap) are important considerations. Are these available, affordable and easily accessible in the workplace? If not, action is needed.

> 3. Check it (monitoring & feedback)

How can you identify the gaps in IPC practices or other indicators in your setting to allow you to prioritize your intervention?

How can you be sure that the intervention is being implemented correctly and safely, including at the bedside? For example, are there methods in place to observe or track practices?

How and when will feedback be given to the target audience and managers? How can patients also be informed?

Practical example: when implementing surgical site infection interventions, the use of key tools are important considerations, such as surveillance data collection forms and the WHO checklist (adapted to local conditions).

5. Live it (culture change)


Is there demonstrable support for the intervention at every level of the health system? For example, do senior managers provide funding for equipment and other resources? Are they willing to be champions and role models for IPC improvement Are taxes involved in concleasioning or advantion the

Are teams involved in co-developing or adapting the intervention? Are they empowered and do they feel ownership and the need for accountability?


Practical example: when implementing hand hygiene interventions, the way that a health facility approaches this as part of safety and quality improvement and the value placed on hand hygiene improvement as part of the clinical workflow are important considerations.




Integration of hand hygiene in the flow of patient care








Source: <u>http://www.who.int/infection-</u> prevention/tools/surgical/reminders-advocacy/en/



Sources: http://www.who.int/infection-prevention/tools/core-components/en

Preventing surgical site infections: implementation approaches for evidence-based recommendations. Geneva: World Health Organization; 2018 (<u>http://www.who.int/infection-prevention/tools/surgical/en/</u>).





Operational manual for the WHO SSI prevention recommendations.

This implementation manual is designed to be used by all persons concerned by the prevention of SSI in all health care settings, irrespective of the country.

Launched in December 2018

http://www.who.int/infection-prevention/tools/surgical/en/

Bringing improvement to life



- Example Scenario
- Problem
- Case study



New WHO implementation package for SSI prevention



Infection prevention and control Surgical site infections tools and resources Home page Link to Global guidelines on the prevention of surgical site infection publications page A range of tools exist for you to adopt and adapt to support local improvement. About us They are proven to achieve change if used as part of a multi-modal strategy as represented in the 5 components listed here. Campaigns Implementation tools and resources Communications for System change awareness raising Evidence, guidelines and publications Training and education Institutional safety climate i. and culture Work in countries News and events Evaluation and feedback R Check it Teach it training and education é do Sell it reminders and Build it communications system change S Live it http://www.who.int/infection-prevention/tools/surgical/en/ culture change

WHO core component 5 for effective IPC Strong recommendation: multimodal strategies



- National level: national IPC programmes should coordinate and facilitate the implementation of IPC activities through multimodal strategies on a nationwide or subnational level.
- Facility level: IPC activities using multimodal strategies should be implemented to improve practices and reduce HAI and AMR.
- A multimodal strategy comprises several elements or components (three or more; usually five) implemented in an integrated way with the aim of improving an outcome and changing behaviour. It includes tools, such as bundles and checklists, developed by multidisciplinary teams that take into account local conditions.
- The five most common components are: (i) system change (availability of the appropriate infrastructure and supplies to enable IPC recommendations implementation); (ii) education and training of health care workers and key players; (iii) monitoring infrastructures, practices, processes, outcomes and providing data feedback; (iv) reminders in the workplace/communications; and (v) culture change within the establishment or the strengthening of a safety climate.

Source: Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016 (http://www.who.int/infection-prevention/publications/ipc-core-components/en/).

Understanding the multimodal strategy for SSI prevention (1)



System change *"Build it"*

- Ensuring that the health care facility has the necessary infrastructure and resources in place to allow for steps to be taken to prevent SSI based on the known modifiable risk factors
- The right infrastructure and available resources can streamline interventions for consistent delivery of care and make execution easier and safer.

Source: Preventing surgical site infections: implementation approaches for evidence-based recommendations. Geneva: World Health Organization; 2018 (<u>http://www.who.int/infection-prevention/tools/surgical/en/).</u>

System change - "Build it" (cont') Necessary infrastructure and resources



- Allocated budget
- Standard operating procedures, protocols, local policies and tools/mechanisms for training
- An IT system (or paper) for monitoring and feedback on infrastructure and resources and other improvement steps
- Laboratory services
- Surgical services/human resources including a dedicated, competent team for ensuring SSI prevention activities working to an action plan
- Supplies for surgical hand preparation*
 ABHR, antimicrobial soap
 - * Procurement vs local production

- Sterile drapes and gowns
- The correct antibiotics for SAP (and if need to be given with MBP) - easily accessible
- Clippers (if hair removal essential)
- Chlorhexidine- alcohol-based (skin prep) solution*
- Mupirocin 2% ointment
- Oxygen
- Standard postoperative wound dressings To consider:
- Antimicrobial-coated sutures
- Negative pressure wound therapy devices
- Nutritional formulas
- Warming devices
- Fluid therapy
- Aqueous povidone iodine solution (irrigation)

Understanding the multimodal strategy for SSI prevention (2)

Training and education – "Teach it"

- Practical training and education methods aligned with the recommendations for SSI prevention
- Onsite hospital courses
- Bolus (single relatively large) sessions
- Simulation sessions for skills training
- Use of locally made or online videos
- Online e.learning courses and webinars
- Focus groups and workshops
- Bedside training
- In-person sessions, e.g. during ward or grand rounds, town hall meetings, coaching visits
- Pre and post knowledge and perception tests
- Training support materials (handouts, e-learning, etc.)





Understanding the multimodal strategy for SSI prevention (3)



Evaluation and feedback

"Check it"

Regular **monitoring** and timely **feedback** of:

- risk factors for SSI;
- compliance with recommended procedures and practices;
- infrastructures and available resources and supplies;
- knowledge and perception of the problem;
- SSI rates.

It should not be seen as a component separate from implementation or only to be used for scientific purposes. Targeted tools and use of observations are inherent.

This is an essential step in:

- identifying areas deserving major efforts and feeding crucial information into development of local local action plan;
- measuring the changes induced by improvement efforts and ascertaining whether interventions have been effective;
- engaging staff in deciding upon different formats for providing feedback (real time and personalised feedback have proven beneficial).

Understanding the multimodal strategy for SSI prevention (4)

Reminders and communications

"Sell it"

- **Reminding and prompting** health care workers about the importance of practices to prevent SSI when they are working at the point of care
- Informing patients and their visitors of the standard of care that they should expect to receive
- **Communications** to inform senior leaders and decision-makers regarding the standards that they should assure



- Posters
- Leaflets
- Banners
- Stickers
- Flowcharts
- Infographics
- Letter templates
- Advocacy messages suitable to the local setting, e.g. memos
- Manuals
- Electronic reminders (built in to hospital IT system)
- Telephone call (including for patient reminders)

Understanding the multimodal strategy for SSI prevention (5)



Institutional safety climate and culture

"Live it"


Creating an **environment and the perceptions** that facilitate awareness-raising about SSI prevention at all levels:

- a climate that understands and prioritizes surgical safety issues;
- team spirit and cohesion;
- awareness of self-capacity to make a change, ownership of the intervention.

- Motivated, multidisciplinary well functioning teams
- Champions
- Role models
- Visible leadership including on ward/grand rounds, through photographs and signatures
- Morbidity and mortality meetings including senior hospital staff – to learn from defects and facilitate sharing for improvement
- Advocacy messages from leaders (delivered in a timely manner)

Recently launched WHO SSI Prevention Implementation Package World Health Organization





http://www.who.int/infection-prevention/tools/surgical/en/

WHO 2019 Global Survey on
Infection Prevention and Control
and Hand Hygiene
Facility-level assessments
in a spirit of improvementImage: Control Survey on
Control
Image: Control Survey on
Control Survey on
Co





16 January – 16 July

World Health Organization

All health care facilities and countries are invited to participate!

Find instructions here https://www.who.int/infection-prevention/campaigns/ipc-global-survey-2019/en/

System change: modified WHO formulations for surgical hand preparation

World Health Organization

Formulation I

Final concentrations: ethanol 80% wt/wt, glycerol 0.725% vol/vol, hydrogen peroxide 0.125% vol/vol.

Ingredients:

- 1. ethanol (absolute), 800 g
- 2. H₂O₂ (3%), 4.17 ml
- 3. glycerol (98%), **7.25 ml** (or 7.25 x 1.26 = 9.135 g)
- 4. top up to **1000 g** with distilled or boiled water

Sources:

Suchomel M KM, Kundi M, Pittet D, Rotter ML. Modified World Health Organization hand rub formulations comply with European efficacy requirements for preoperative surgical hand preparations. Infect Control Hosp Epidemiol. 2013; 34(3):245–250.

 Allegranzi B, Aiken AM, Zeynep Kubilay N, Nthumba P, Barasa J, Okumu G et al. A multimodal infection control and patient safety intervention to reduce surgical site infections in Africa: a multicentre, before–after, cohort study. Lancet Infect Dis. 2018; 18(5):507–515.

Formulation II

Final concentrations: isopropanol 75% wt/wt, glycerol 0.725% vol/vol, hydrogen peroxide 0.125% vol/vol.

Ingredients:

1. isopropanol (absolute), 750 g

2. H₂O₂ (30%), **4.17 ml**

3. glycerol (98%), **7.25 ml** (or 7.25 x

1.26 = 9.135 g)

4. top up to **1000 g** with distilled water



Education and training example: improving surgical hand preparation

1. Local production of modified WHO formulation for ABHR

- 2. Surgical hand preparation
 - Antimicrobial soap + water = 2–5 minutes
 - **Alcohol-based** = 1.5–3 minutes
 - The right technique is crucial
 - Nailbrushes are <u>not</u> recommended.









Education and training example

 \equiv



University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland





Infection Control & Improving Practices

Monitoring example – observation tools



World Health Organization					Patient Safety A World Alilance for Safer Health Care					SAVE LIVES Clean Your Hands					
Ob	serv	ati	on Fo	rm											
Facility:				Period Number*:					Session Number*:						
Servi	Service: Ward: Department:		Date: (dd/mm/yy)			/	1		Observer: (initials)						
Ward				Start/End time: (hh:mm)				/ : Page N°:		N°:					
Dono					Session duration: (mm)				014.44	City**:					
Depa	rtment:										City	:			
	rtment: htry**:										City	:			
	ntry**:			Prof	cat			Prof.	cat		City	Prof	cat		
Coun	ntry**: cat			Prof.				Prof. Code			City				
Cour Prof.	ntry**: cat										City	Prof.			
Coun Prof. Code	ntry**: cat	on	HH Action	Code N°	,		HH Action	Code		cation	HH Action	Prof. Code Nº		lication	HH Actior
Coun Prof. Code N°	ntry**: cat	oat. isept. .f. at.	HH Action HR HW O missed O glovos	Code N°	India	(mm)	HH Action HR HW O missed O gloves	Code N°		cation pef-pat. pef-asept. aft-b.f. aft-pat. aft.p.surr.		Prof. Code Nº		lication bef-pat. bef-asept. aft-b.f. aft-pat. aft.p.surr.	HH Action





Sources:

- <u>http://www.who.int/infection-prevention/tools/hand-hygiene/evaluation_feedback/en/</u>
- Protocol for surgical site infection surveillance with a focus on settings with limited resources. Geneva: World Health Organization; 2018 (http://www.who.int/infection-prevention/tools/surgical/evaluation_feedback/en/).

Reminders

Surgical Handrubbing Technique

- Handwash with soap and water on arrival to OR. after having donned theatre clothing (cap/hat/bonnet and mask).
- Use an alcohol-based handrub (ABHR) product for surgical hand preparation, by carefully following the technique illustrated in Images 1 to 17, before every surgical procedure.
- If any residual talc or biological fluids are present when gloves are removed following the operation, handwash with soap and water.



Put approximately 5ml Dip the fingertips of your (3 doses) of ABHR in the right hand in the handrub to palm of your left hand, using decontaminate under the the elbow of your other arm nails (5 seconds). to operate the dispenser.



............

........

Put approximately 5ml

(3 docec) of ABHR in the palm

Images 3-7: Smear the handrub on the right forearm up to the elbow. Ensure that the whole skin area is covered by using circular movements around the forearm until the handrub has fully evaporated (10-15 seconds).



Rub palm against palm

interlinked

back and forth with fingers

Images 8-10: Now repeat steps 1-7 for the left hand and forearm.

3





12

Cover the whole surface of

the hands up to the wrist

with ABHR, rubbing palm

against palm with a

rotating movement.

Rub the thumb of the left When the hands are dry,

hand by rotating it in the sterile surgical clothing and clasped palm of the right gloves can be donned hand and vice versa.

Repeat this sequence (average 60 sec) the number of times that adds up to the total duration recommended by the ABHR manufacturer's instructions This could be two or even three times.

Rub the back of the fingers

by holding them in the palm

of the other hand with a

sideways back and forth

movement



Rub the back of the left

hand, including the wrist,

and forth, and vice-versa.

moving the right palm back

Source: http://www.who.int/infectionprevention/tools/surgical/reminders-advocacy/en/





Reminders and communications: campaigning poster





Source: http://www.who.int/gpsc/5may/A4 hh-poster-visual-EN.pdf?ua=1



Reminders: embedding hand hygiene in the surgical patient's journey



<section-header><text>

Key additional considerations for post-operative wounds

 Avoid unnecessary touching of the post-operative wound site, including by the patient.

Wear gloves it contact with body \$uids is anticipated; the need for hand hygiene does not change even it gloves are worn, as per the WHO 5 Moments.
 Follow local procedures regarding use of assiptic non-bouch technique for any required dressing changes/wound procedures.

 Don't touch chessings for at least 48 hours after surgery, unless leakage or other complications occur.

 Routine post-operative wound dressings should be basic dressing types (e.g. absorbent or low adherence dressings).

 When approaching a patient for the examination of a wound, the health worker may also perform other tasks (e.g. accessing a venous catheter, drawing blood samples, checking urinary catheter). Hand hygiene may be needed before and after these specific tasks, to once again fulfil Monrerts 2 and 3, for exempte jetter to WHO addicated 3 Monrents posters for time or adthetim management). When indicated, pre-operative surgical arbitratic prophytics (IAP) should be administered as a single pareterized does 2 hours or lens before the surgical incision, while considering the helf-life of the artibiotic. On on protong administered or SAP there computing into 1 the genetiation.

 Antibiolic through for any preven surgical site infection should ideally be astromistered based on wound sample curue and senability results.
 Common signs and symptoms of wound infection are: pain or tendenrees; localized seeking: enythema; heat, or purulent drainage from the superficial incision.

from the superficial incision. • This guidance does not include information on complicated post-operative wound care, when specific treatments or therapies may be required.

World Health Organization

SAVE LIVES

Source: <u>http://www.who.int/infection-</u> prevention/tools/surgical/reminders-advocacy/en/



Tools to address the culture



Core CUSP toolkit

Created for clinicians by clinicians, the CUSP toolkit is modular and modifiable to meet individual unit needs. Each module includes teaching tools and resources to support change at the unit level, presented through facilitator notes that take you step-by-step through the module, presentation slides, tools, videos.

CUSP for Safe Surgery Perioperative Staff Safety Assessment


Purpose of this form: The purpose of this form is to tap into your experiences at the frontlines of patient care to find out what risks jeopardize patient safety in your clinical area.
Who should complete this form: All staff members.
How to complete this form: Provide as much detail as possible when answering the 4 questions. Drop off your completed safety assessment form in the location designated by the SUSP team.
When to complete this form: Any staff member can complete this form at any time.

	CUSP for Safe Surgery (SUSP) Safety Issues Worksheet for Senior Executive Partnership							
	Date of Safety Rounds:							
1	Unit:							
	Attendees:							
	1.	5.						
	2.	6.						
	3.	7.						
-	4.	(Please use back of form for additional attendees.)						

Sources: Core CUSP Toolkit [website]. Rockville, MD: Agency for Healthcare Research and Quality; 2018 (<u>https://www.ahrq.gov/professionals/education/curriculum-tools/cusptoolkit/modules/index.html);</u> Supplemental Tools [website]. Rockville, MD: Agency for Healthcare Research and Quality; 2018 (<u>https://www.ahrq.gov/professionals/quality-patient-</u> <u>safety/hais/tools/surgery/guide-appcusp.html</u>).

SSI prevention throughout the patient journey – IPC in action







Source: http://www.who.int/gpsc/ssi-infographic.pdf

Acknowledgements



- Benedetta Allegranzi (Department of Service Delivery and Safety, WHO) coordinated the development of this module and contributed to its writing.
- Claire Kilpatrick (Department of Service Delivery and Safety, WHO) led the writing of the module.
- Anthony Twyman and Nizam Dimani (Department of Service Delivery and Safety, WHO) contributed to the writing of the module.

THANK YOU

WHO Infection Prevention and Control Global Unit



Learn more at: http://www.who.int/infection-prevention/en/

